Table 2.
Results of the interrupted time series analysis for initiation of osteoporosis investigations and treatments, combined across the three sites*
| Outcomes | Mean of proportions across the three sites (SD) | % Increase | P value † | |
|---|---|---|---|---|
| Baseline | Intervention | |||
| Initiation of BMD testing | 2.79 (1.27) | 6.15 (2.24) | 3.4 | <0.001 |
| 95% CI | 1.86 to 3.74 | 3.38 to 8.42 | 2.03 to 4.68 | |
| Initiation of any osteoporosis medication ‡ | 0.42 (0.36) | 0.87 (0.66) | 0.5 | 0.006 |
| 95% CI | 0 to 1.13 | 0 to 2.16 | 0.15 to 0.85 | |
| Initiation of calcium + vitamin D | 0.70 (0.56) | 1.58 (0.95) | 0.9 | <0.001 |
| 95% CI | 0 to 1.80 | 0 to 3.44 | 0.39 to 1.41 | |
| Initiation of any nutritional supplement (calcium or vitamin D) | 0.97 (0.71) | 2.13 (1.28) | 1.2 | 0.001 |
| 95% CI | 0 to 2.36 | 0 to 4.64 | 0.49 to 1.91 | |
*BMD, bone mineral density; SD, standard deviation.
†From autoregressive integrated moving-average (ARIMA) model. Intercept only model is fitted since the slopes are not significantly different from zero.
‡The following osteoporosis medications were considered: any bisphosphonate (alendronate, etidronate, risedronate, zoledronic acid), any selective estrogen receptor modulator (e.g., raloxifene), nasal calcitonin, parathyroid hormone, and hormone replacement therapy.